ArticleEuropean heart journal2023

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.

Gregory G Schwartz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.